Protalix Biotherapeutics (PLX) Stock Price, Quote & News

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 696 9345

Website: www.protalix.com

Address:

2 University Plaza, Suite 100, Hackensack, United States

jcon777 Jul. 4 at 7:37 PM

$PLX I'm curious if anyone has ideas where I could post some fun and helpful AI generated Protalix pics that might inform Fabry patients of the superiority of Elfabrio. Maybe there are some Fabry boards where some fun and creative AI Protalix pics might help. Maybe someone here already has access to another board or group, then you could just tell me what you want the pic to say and look like, and i could create it here, and you could copy & post it.

1 · Reply

CliffordCapital Jul. 4 at 9:21 AM

$PLX happy July 4th to my American brothers and sisters!! May god bless you $WVE $IREN $EOSE $VSTM

0 · Reply

annushka Jul. 4 at 12:38 AM

$PLX Happy Birthday America! Happy Independence Day my friends!!!

2 · Reply

PLX_BULLS Jul. 3 at 10:39 PM

$PLX “next generation ERT like Elfabrio/unigal”!

0 · Reply

PLX_BULLS Jul. 3 at 10:38 PM

$PLX from a few months ago… good see these type of thoughts from a hospital!

0 · Reply

CliffordCapital Jul. 3 at 3:07 PM

$PLX last year to get this stock below 5$

1 · Reply

Merlintrader Jul. 3 at 5:56 AM

$PLX Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub Updated july 3 https://www.merlintrader.com/protalix-biotherapeutics-stock-hub/

0 · Reply

jcon777 Jul. 3 at 4:11 AM

$PLX And one more for marketing to use if you want it.

0 · Reply

jcon777 Jul. 3 at 4:03 AM

$PLX Marketing team, feel free to use this pic or change it a bit. 😎

0 · Reply

TheMotleyMonk Jul. 2 at 7:41 PM

$PLX Hot off the wires...maintains $11 p/s fair value: https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/d1w0zxn7-ema-reviews-and-rare-disease-trends-will-open-global-markets-whhq

0 · Reply

Protalix BioTherapeutics Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 7 weeks ago

Protalix BioTherapeutics Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 7 weeks ago

Protalix BioTherapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Protalix BioTherapeutics Slides: Corporate presentation

May 13, 2026, 6:50 AM EDT - 7 weeks ago

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 6, 2026, 6:50 AM EDT - 2 months ago

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Protalix BioTherapeutics Proxy statement: Proxy filing

Mar 18, 2026, 8:00 AM EDT - 3 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:00 AM EDT - 3 months ago

Protalix BioTherapeutics Annual report: Q4 2025

Mar 18, 2026, 8:00 AM EDT - 3 months ago

Protalix BioTherapeutics Earnings release: Q4 2025

Mar 18, 2026, 6:50 AM EDT - 3 months ago

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Mar 11, 2026, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

2026-03-09T10:16:17.000Z - 4 months ago

Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio

Mar 9, 2026, 6:00 AM EDT - 4 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

2026-01-30T14:56:18.000Z - 5 months ago

Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing

Jan 30, 2026, 9:47 AM EST - 5 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Jan 30, 2026, 9:47 AM EST - 5 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Jan 5, 2026, 6:50 AM EST - 6 months ago

Protalix BioTherapeutics Letter to Stockholders

Dec 17, 2025, 6:50 AM EST - 7 months ago

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

2025-11-21T11:10:30.000Z - 8 months ago

Protalix price target lowered to $12 from $15 at H.C. Wainwright

Nov 13, 2025, 8:00 AM EST - 8 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Protalix BioTherapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Protalix BioTherapeutics Earnings release: Q3 2025

Nov 13, 2025, 6:50 AM EST - 8 months ago

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Nov 6, 2025, 6:50 AM EST - 8 months ago

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

2025-10-17T11:11:05.000Z - 9 months ago

Protalix, Chiesi Global: CHMP issues negative opinion for Elfabrio

Oct 17, 2025, 6:58 AM EDT - 9 months ago

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

Sep 16, 2025, 10:30 AM EDT - 10 months ago

Protalix BioTherapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 11, 2025, 10:55 AM EDT - 10 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 2, 2025, 6:50 AM EDT - 10 months ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Protalix BioTherapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Protalix BioTherapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Protalix BioTherapeutics Registration statement: Registration Filing

Aug 14, 2025, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Aug 7, 2025, 12:53 PM EDT - 11 months ago

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

2025-07-21T10:55:33.000Z - 1 year ago

Protalix appoints Gilad Mamlok as CFO

Jul 21, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

2025-06-30T14:45:15.000Z - 1 year ago

Protalix added to Russell 3000, Russell 2000 Indexes

Jun 30, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

May 20, 2025, 4:30 PM EDT - 1 year ago

Protalix BioTherapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings release: Q1 2025

May 9, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 5, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

2025-04-28T21:05:49.000Z - 1 year ago

Protalix files $100M mixed securities shelf

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Protalix BioTherapeutics Registration statement: Registration Filing

Mar 24, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

2025-03-20T01:55:45.000Z - 1 year ago

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2024

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Annual report: Q4 2024

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings release: Q4 2024

Mar 17, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Mar 10, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Feb 4, 2025, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

2025-02-03T11:15:19.000Z - 1 year ago

Protalix price target raised to $15 from $10 at H.C. Wainwright

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

2024-12-09T12:12:11.000Z - 1 year ago

Protalix, Chiesi announce EMA validation of pegunigalsidase Variation Submission

Dec 9, 2024, 6:30 AM EST - 1 year ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Quarterly report: Q3 2024

Nov 14, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Nov 7, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Oct 25, 2024, 7:18 AM EDT - 1 year ago

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Sep 16, 2024, 8:35 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Sep 4, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Quarterly report: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q2 2024

Aug 14, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Aug 7, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Transcript: Investor Day 2024

Jun 13, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

May 29, 2024, 8:38 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the 2024 BIO International Convention

May 17, 2024, 8:00 AM EDT - 2 years ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2024

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Quarterly report: Q1 2024

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q1 2024

May 10, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

May 3, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Annual report: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q4 2023

Mar 14, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Mar 7, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Feb 23, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Dec 26, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Quarterly report: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Earnings release: Q3 2023

Nov 6, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Oct 30, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

jcon777 Jul. 4 at 7:37 PM

1 · Reply

CliffordCapital Jul. 4 at 9:21 AM

$PLX happy July 4th to my American brothers and sisters!! May god bless you $WVE $IREN $EOSE $VSTM

0 · Reply

annushka Jul. 4 at 12:38 AM

$PLX Happy Birthday America! Happy Independence Day my friends!!!

2 · Reply

PLX_BULLS Jul. 3 at 10:39 PM

$PLX “next generation ERT like Elfabrio/unigal”!

0 · Reply

PLX_BULLS Jul. 3 at 10:38 PM

$PLX from a few months ago… good see these type of thoughts from a hospital!

0 · Reply

CliffordCapital Jul. 3 at 3:07 PM

$PLX last year to get this stock below 5$

1 · Reply

Merlintrader Jul. 3 at 5:56 AM

$PLX Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub Updated july 3 https://www.merlintrader.com/protalix-biotherapeutics-stock-hub/

0 · Reply

jcon777 Jul. 3 at 4:11 AM

$PLX And one more for marketing to use if you want it.

0 · Reply

jcon777 Jul. 3 at 4:03 AM

$PLX Marketing team, feel free to use this pic or change it a bit. 😎

0 · Reply

TheMotleyMonk Jul. 2 at 7:41 PM

0 · Reply

Andrea31 Jul. 2 at 6:56 PM

$PLX So guys, based on my calculations, Protalix's revenues for 2030 come out to $170–180 million. I have no idea what kind of profit that will mean. And that is the calculation excluding the effect of PRX-115.

2 · Reply

Neil_Armstrong Jul. 2 at 2:06 PM

$PLX ok so what’s the bull case then the bear case here? I’m bored so not sure if I should keep this

1 · Reply

YoDai Jul. 1 at 12:35 PM

$PLX plx move - daddy needs to pay his bills 😅🤣🤣🤣

1 · Reply

ed29 Jun. 30 at 6:42 PM

$PLX I now understand why Elzocko blocked me for saying global warming is / was / and always will be a hoax.

3 · Reply

PLX_BULLS Jun. 30 at 4:22 PM

$PLX I wish they would make a PLX punching and kicking bag…. That way I could let out my frustrations on it.

2 · Reply

Supreme10 Jun. 30 at 7:53 AM

$PLX Sobi has received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for NASP (nanoencapsulated sirolimus plus pegadricase) for the treatment of adult patients with uncontrolled gout. In the CRL, the Food and Drug Administration requires the company to submit additional data, primarily related to the manufacturing and control strategy for the biological component of NASP, as well as to address deficiencies at a contract manufacturing facility. The Food and Drug Administration has not identified any concerns regarding the clinical efficacy or safety of NASP that would preclude approval. Sobi will request a meeting with the FDA to discuss the feedback, determine the appropriate steps for a resubmission, and work with the contract manufacturers to resolve the deficiencies.

1 · Reply

woodbarn Jun. 29 at 9:54 PM

$PLX Sobi's NASP, a yeast uricase for gout, had a PDUFA date for June 27, 2026.

1 · Reply

Paperglider Jun. 29 at 8:48 PM

$PLX This is the composition-of-matter plus process family underlying PRX-115. Expiration is Nov 3, 2041 with possible extension up to 5 years due to regulatory delays. Title: "Modified Uricase and Uses Thereof" Application: 18/035,149 — US national-stage entry of PCT/IL2021/051305 Applicant/assignee: Protalix Ltd. (Carmiel, Israel) Inventors: Ruderfer, Nataf, Arvatz, Hanania, Ariel, Rozen, Hayon (all Israel-based)

0 · Reply

Social_Idiot Jun. 29 at 8:48 PM

$PLX $SLS @richardxkxkTwits The proof. This was before I was done taking my loss in PLX. I thought I'd pass on a Christmas bump. I may have mentioned before but didn't link the 2 tickers.

1 · Reply

Paperglider Jun. 29 at 8:37 PM

$PLX Modified Uricase and Uses Thereof - Patent to be issued on 07/07/2026 (06/24/2026 issue notification) - might explain price rise

0 · Reply

richardxkxkTwits Jun. 29 at 8:19 PM

$PLX at least someone from old plx board went all in with $SLS

1 · Reply

jcon777 Jun. 29 at 6:53 PM

$PLX Earnings Whisper has often been wrong. Here is what they predict anyway for next earnings: Thursday Aug 13 Consensus: $-0.01, Revenue: $37.79 Mil https://www.earningswhispers.com/stocks/PLX

0 · Reply

Market Cap	186.93M
Revenue (ttm)	52.74M
Net Income (ttm)	-6.60M
EPS (ttm)	N/A
PE Ratio	12.78
Forward PE	11.80
Profit Margin	-12.51%
Debt to Equity Ratio	0.00

Volume	472,700
Avg Vol	757,336
Day's Range	N/A - N/A
Shares Out	80.57M
Stochastic %K	76%
Beta	0.00
Analysts	Strong Sell
Price Target	$11.00